羟苯磺酸钙治疗糖尿病微血管并发症的机制及临床获益  

Mechanism and clinical benefit of calcium dobesilate in treatment of diabetic microvascular complications

作　　者：余洋[1] 黄仲义[2] YU Yang;HUANG Zhong-yi(Department of Eindocrinology,Peking University First Hlospital,BElIJING 100034,China;Shanghai Jing-an DistrictCentral Hospital,SHANGHAl 200040,China)

机构地区：[1]北京大学第一医院内分泌科,北京100034 [2]上海市静安区中心医院,上海200040

出　　处：《中国新药与临床杂志》2021年第12期811-815,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：羟苯磺酸钙是一种血管保护药物,具有抗炎、抗氧化应激、改善内皮功能紊乱等多种作用。研究表明羟苯磺酸钙可有效改善糖尿病视网膜病变患者的临床症状,并延缓视网膜病变的进展,同时还可以降低糖尿病肾病患者的尿白蛋白排泄率。此外,羟苯磺酸钙主要以原型双通道排泄,肝、肾负担轻,临床不良反应少,已被多个指南/专家共识推荐用于治疗糖尿病微血管病变。Calcium dobesilate is an established vasoactive and angioprotective drug that has the effect of antiinflammation, anti-oxidative stress, and improving endothelial dysfunction. Studies have shown that calcium dobesilate can effectively improve the clinical symptoms of patients with diabetic retinopathy and delay the disease progression. It can also reduce the urinary albumin excretion rate of diabetic nephropathy patients. Moreover, calcium dobesilate is mainly excreted by the original double channel, with light burden on the liver and kidney and few clinical adverse reactions. Therefore, it is recommended by many guidelines/experts as a drug for the treatment of diabetic microangiopathy.

关 键 词：羟苯磺酸钙 分子结构 糖尿病血管病变 药理作用分子作用机制 

分 类 号：R587.23[医药卫生—内分泌] R973.1[医药卫生—内科学]